Results 211 to 220 of about 74,999 (298)

TREM2 in Macrophages Promotes Renal Fibrosis via Activation of β‐Catenin Signalling Pathway in Obstructive Nephropathy

Cell Proliferation, EarlyView.
Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) promotes obstructive nephropathy progression by activating the β‐catenin signalling pathway, driving M2 macrophage polarisation, migration and fibrogenic gene expression. targeted inhibition of TREM2 thus represents a promising novel strategy against renal fibrosis.
Jia Wei, Zixia Li, Gengyu Du, Ting Chen, Min Yang, Zhen Yuan, Yidan Zheng, Xiang Yan   +7 more
wiley   +1 more source

Glycyrrhizin preparations in liver diseases: a narrative review of mechanisms and therapeutic potential. [PDF]

Front Pharmacol
Ma T, Hao H, Wang S, Qiu D, Cao W, Deng W, Wang S, Li X, Zhang Z, Wei X, Yao L, Gao Z, Yi W, Liu R, Li M.   +14 more
europepmc   +1 more source

Single Cell Multi‐Omics Revealing the Important Role of MR1 Mediated MAIT Cells in Maintaining Rejection for Liver Transplantation

Cell Proliferation, EarlyView.
This multi‐omics study reveals the significant role of MAIT cells in liver transplant rejection. MAIT cells drive rejection in liver transplantation via the MR1 axis. Their absence reshapes T cell responses and clonal expansion, attenuating allograft injury.
Hailun Cai, Xinqiang Li, Xin Zhou, Xueteng Wang, Zhuoyu Jia, Ruidong Ding, Yurong Luo, Ye Wang, Shipeng Li, Wenxing Sun, Dongxing Wu, Dahong Teng, Kai Zhao, Guanghui Pei, Jinzhen Cai, Bin Wu   +15 more
wiley   +1 more source

Multimorbidity patterns and their associations with healthcare services utilisation in inpatients with chronic hepatitis B infection from 2011 to 2023: a retrospective observational study. [PDF]

BMJ Open
Wang X, Xie J, Wu Y, Chen G, Ao H, Liu Z, Jie Y, Gu J.   +7 more
europepmc   +1 more source

S3 guideline diagnostics and therapy in alopecia areata – Part 2: Therapy, psychosocial and cosmetic support

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary This second part of the S3 guideline on the diagnosis and treatment of alopecia areata (AA), presents key recommendations on topical and systemic therapy, quality of life and support services. The first part of the guideline, published separately, covers the definition and content of epidemiology and diagnosis as well as comorbidities, risk and
Ulrike Blume‐Peytavi, Andria Constantinou, Tsenka Tomova‐Simitchieva, Adrian Tanew, Michael Sticherling, Hermann Girschick, Annika Vogt, Uwe Schwichtenberg, Uwe Gieler, André Märtens, Kerstin Zienert, Claudia Stenders, Ricardo Niklas Werner, Doris Wilborn   +13 more
wiley   +1 more source

Prognostic associations of vitamin D deficiency with disease severity, survival, and complications in alcohol-related liver disease. [PDF]

Front Med (Lausanne)
He Q, Duan F, Mao C, Cheng J, Wang Y, Zeng Y, Yang S.   +6 more
europepmc   +1 more source

Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE‐JP Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon‐like peptide‐1 receptor (GLP‐1R) dual agonist with the potential to induce greater weight reductions than GLP‐1R mono‐agonists. We report the design and baseline participant characteristics of the
Koutaro Yokote, Toshimasa Yamauchi, Yasushi Fukushima, Yoji Takatsuka, Marie Kato, Shijia Yan, Takayoshi Inoue, Luiza Borowska, Martina Brueckmann, Wataru Ogawa, on behalf of the SYNCHRONIZE‐JP Trial Investigators   +10 more
wiley   +1 more source

The Key Role of Complement Receptor CRIg in Kupffer Cell-Mediated Liver Disease Progression. [PDF]

Viruses
Sun XZ, Liu Y.
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction‐Associated Steatotic Liver Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Treatment options for metabolic dysfunction‐associated steatotic liver disease (MASLD) are limited. While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver‐related outcomes remains unclear.
Gregor A. Maier, Ramon A. Hofmann, Michael Roden, Wolfgang Rathmann, Oliver Kuss   +4 more
wiley   +1 more source

Herbal remedies for hepatic diseases: A review of medicinal herbs in the treatment of liver disorders. [PDF]

Chin Herb Med
Saraswat I, Goel A, Gupta J.
europepmc   +1 more source